And it might specifically target AML patients harboring FMS-like tyrosine kinase 3 (FLT3) or DNA methyltransferase 3A (DNMT3A) mutations (79), which holds immense potential for clinical application but awaits further in-depth investigations. The gene discussed is FLT3; the disease is acute myeloid leukemia.